DOC1 inhibitors represent a class of chemical compounds designed to target and modulate the activity of the DOC1 protein. However, it's important to note that DOC1 alone does not specify a particular protein or molecule within the context of biology or chemistry, as it seems to be an abbreviation or placeholder for the actual target molecule or protein. In scientific research, compounds designated as DOC1 inhibitors are typically created to interact with and modulate the function of a specific protein or molecule with a name or classification that begins with DOC1. These inhibitors are developed to influence the biological processes associated with the target molecule, which can vary widely depending on the specific identity of the molecule denoted as DOC1.
The mechanisms by which DOC1 inhibitors function and their chemical structures can greatly differ based on the nature and function of the specific DOC1 target molecule. These inhibitors may interact with DOC1 through various mechanisms, such as binding directly to the target, disrupting its activity, altering its conformation, or influencing its interactions with other cellular components. The ultimate goal of DOC1 inhibitors is to interfere with the normal function or activity of the target molecule, thereby affecting the biological processes it regulates. Ongoing research in this area aims to elucidate the precise mechanisms and downstream effects of DOC1 inhibition and to identify potential applications of these inhibitors in various scientific contexts where the specific DOC1 target molecule is relevant.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
A potent, selective inhibitor of CDK2, thus indirectly affecting DOC1-associated pathways. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Inhibits CDK2, indirectly impacting DOC1 functions in cell cycle regulation. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Targets CDK2 among other cyclin-dependent kinases, potentially altering DOC1 activity. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Broad CDK inhibitor, can indirectly affect DOC1 through CDK2 inhibition. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Strongly inhibits CDK2, likely to influence DOC1-related pathways. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
Inhibits CDK2, among others, potentially modulating DOC1 activity indirectly. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
Known to inhibit CDK2, may affect DOC1-related cell cycle processes. | ||||||
SU 9516 | 377090-84-1 | sc-222330 sc-222330A | 5 mg 25 mg | $122.00 $383.00 | 3 | |
Selective CDK2 inhibitor, can indirectly influence DOC1 function. | ||||||
CVT-313 | 199986-75-9 | sc-221445 sc-221445A sc-221445B | 1 mg 5 mg 50 mg | $102.00 $408.00 $2550.00 | 17 | |
Specific inhibitor of CDK2, potentially affecting DOC1 by this pathway. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Targets multiple CDKs including CDK2, potentially impacting DOC1. | ||||||